Tivic Health Systems Inc. has provided an update on its recent acquisition of certain contract development and manufacturing organization $(CDMO)$ assets, now branded as Velocity Bioworks. According to the company, the integration of these assets has already led to lower costs, reduced outsourcing delays, and accelerated the validation of the manufacturing process for Entolimod™. Tivic believes this move will allow it to submit a biologics license application to the U.S. Food and Drug Administration ahead of schedule. Additionally, Velocity Bioworks is now operating as a stand-alone CDMO, offering fast, high-quality biologic production services to third-party customers, particularly targeting small and medium-sized development-stage biotechnology companies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1125485) on January 08, 2026, and is solely responsible for the information contained therein.
